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Abstract
Avian influenza continues to circulate and remains a global health threat not least because
of the associated high mortality. In this study antibody persistence, booster vaccine
response and cross-clade immune response between two influenza A(H5N1) vaccines
were compared. Participants aged over 18-years who had previously been immunized with
a clade 1, A/Vietnam vaccine were re-immunized at 6-months with 7.5 μg of the homolo-
gous strain or at 22-months with a clade 2, alum-adjuvanted, A/Indonesia vaccine. Blood
sampled at 6, 15 and 22-months after the primary course was used to assess antibody per-
sistence. Antibody concentrations 6-months after primary immunisation with either A/Viet-
nam vaccine 30 μg alum-adjuvanted vaccine or 7.5 μg dose vaccine were lower than 21-
days after the primary course and waned further with time. Re-immunization with the clade
2, 30 μg alum-adjuvanted vaccine confirmed cross-clade reactogenicity. Antibody cross-
reactivity between A(H5N1) clades suggests that in principle a prime-boost vaccination
strategy may provide both early protection at the start of a pandemic and improved antibody
responses to specific vaccination once available.
Trial Registration: ClinicalTrials.gov NCT00415129
Introduction
The first influenza pandemic of the 21st century in 2009 was caused by a novel influenza A
(H1N1) strain that was first recognized in Mexico [1] and not by the A(H5N1) strain as was
anticipated. However, the threat posed by avian influenza viruses, including the A(H5N1)
viruses, persists.
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The A(H5N1) virus is enzootic in some parts of Africa and Asia resulting in regular out-
breaks in poultry and wild birds. Human cases of A(H5N1) peaked in 2006 but new cases con-
tinue to be diagnosed and a total of 844 confirmed infections has been reported to theWorld
Health Organization (WHO) to date [2]. Whereas the pandemic A(H1N1) 2009 influenza
strain had a mortality very similar to that of seasonal influenza, the mortality associated with A
(H5N1) and A(H7N9) avian viruses is approximately 60% and 30%, respectively [2]. The
higher mortality rate associated with avian influenza is in part due to the lack of pre-existing
immunity against avian derived influenza viruses in the human population. This lack of pre-
existing immunity also explains the poor antibody responses to A(H5N1) vaccines.
Sporadic transmission of (H5N1) influenza virus amongst close household contacts has
been observedbut sustained human-to-human transmission has not yet been reported [3].
Five key amino acid gene mutations that have been demonstrated to occurwhen the virus is
passaged through ferrets suffice to make the virusmore transmissible. Therefore continued vig-
ilance is warranted and preparedness plans need to be maintained [4]. The 2009 A(H1N1)
influenza outbreak uncovered the shortcomings of existing preparedness plans, more specifi-
cally the inability of the community as a whole to respond quickly to the emergence of a new
pandemic and the incapacity to develop, manufacture and deliver an effective vaccine to the
target population in time. Two major challenges in designing and implementing a A(H5N1)
pandemic vaccine strategy are anticipating antigenic variants as a result of antigenic drift and
overcoming the weak immunogenicity due to the lack of pre-existing immunity. Both chal-
lenges may be tackled by using a pre-pandemic vaccine to prime the population prior to a pan-
demic. This strategy is based on two assumptions: first, that priming of a population with a
pre-pandemic vaccine will induce and maintain cross-reactive antibodies that will convey pro-
tection against the pandemic virus before the pandemic strain-specific vaccine becomes avail-
able, and second that boostingwith a strain-matched pandemic vaccine will produce faster,
higher and more cross-protective antibody responses in a primed compared to an unprimed
population [5–7].
In this study, antibody persistence, booster response and cross-clade responses in adults
who had been previously vaccinated with two doses of a clade 1 A(H5N1) high dose alum-
adjuvanted or unadjuvanted low dose vaccine were evaluated after re-immunization with an
unadjuvanted low dose vaccine containing the original vaccine strain or a high dose alum-adju-
vanted clade 2 strain.
Methods
A booster immunization was given in an open-label, phase 2 study. The primary phase was
conducted betweenMay and December 2006, and has previously been reported [8]. This sec-
ondary phase was conducted betweenDecember 2006 and October 2008.
The primary study was conducted at 4 study sites in Europe, whereas the booster study con-
ducted in 3 out of these 4 sites.
Study Design
In the previously reported randomized, open-label, uncontrolled phase 2 trial, 600 adults
(divided equally between two age groups: 18 to 60 years and over 60 years) were randomized to
receive 2 doses (D0, D21) of H5N1 clade 1 vaccine containing either 7.5 μg haemagglutinin
without adjuvant or, 30 μg with 600 μg aluminum hydroxide [Al3+] as adjuvant [8].
The booster study, presented here, was conducted in 2 phases. A cohort of participants at
one study site (n = 154) received a booster dose of the 7.5 μg (H5N1) clade 1 vaccine, 6 months
after having received the primary immunization course with the 7.5 μg (H5N1) clade 1 vaccine,
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either without adjuvant or with 30 μg alum. At a later stage and in 2 of the 3 remaining sites,
subjects who had been primed with two doses of the 30 μg alum-adjuvanted vaccine, were
invited to participate at the booster study which implied that they received one booster immu-
nization with a high dose (30 μg) (H5N1) clade 2 alum-adjuvanted A(H5N1) vaccine at month
22 after the primary immunization (Fig 1). Further details about the study design are available
in S1 File clinical trial protocol.
In order to assess antibody persistence all participants were invited to undergo a blood test
at 6 months after starting the study. Thereafter, all participants who did not receive a booster
vaccine at 6 months were invited to have a blood test to assess antibody persistence at 15 and
22 months.
In one study site, parallel to the 22-month clade 2 booster immunization an additional 50 A
(H5N1) vaccine-naïve adults, aged between 18 and 60 years, were recruited to receive a primary
course of the same clade 2 vaccine that was used as booster. These participants received 2 doses
of the vaccine given three weeks apart.
Study Participants
Adults who had previously participated in the primary study were invited to take part in the
follow-up and booster phase [8]. The following exclusion criteria were used for all participants
who took part in the booster phase of the study: systemic hypersensitivity to any component of
a vaccine or life-threatening reaction after previous vaccines; congenital or acquired immuno-
deficiency or receipt of immunosuppressive therapy such as anti-cancer chemotherapy or
long-term systemic corticosteroid therapy (for more than 2 consecutive weeks in the last 3
months before the visit); receipt of blood products within the past 3 months; vaccination within
Fig 1. Study CONSORT diagram. NC: non compliance with protocol; SAE: serious adverse event; WD: voluntary
withdrawal for unspecified reasons; LFU: lost to follow up.
doi:10.1371/journal.pone.0165384.g001
Avian Influenza Vaccination in Adults
PLOS ONE | DOI:10.1371/journal.pone.0165384 November 4, 2016 3 / 13
4 weeks prior to the trial vaccination or vaccination planned within 4 weeks after any trial vac-
cination; pregnancy (confirmed by positive urine test) or a serious adverse event related to the
trial vaccine following vaccination. For the 50 naive participants, recruited to receive clade 2 as
a primary vaccination, the following additional exclusion criteria were applied: chronic illness
that could have interfered with the trial conduct or completion; previous vaccination with
avian influenza vaccine; planned or recent participation in another clinical trial; bleeding disor-
der that prohibited intra-muscular injections or a febrile illness on the day of inclusion.
The study was approved by the institutional ethics review boards based in each participating
Belgium institution (Universities of Antwerp, Ghent and Leuven) and the National Health Ser-
vice Oxford ethics committee for the Oxford site., The study was conducted in accordance with
the Declaration of Helsinki and GoodClinical Practice.Written informed consent was
obtained from all participants before enrolment in this part of the study. The trial is registered
with Clinicaltrials.gov:NCT00415129.
Study Procedures
Blood sampling. Up to 30 ml of bloodwas sampled to assess antibody persistence at 6, 15
and 22-months in the different groups of participants as described above. For those who
received booster immunizations at 6 months, bloodwas sampled prior to and 21 days after
immunization. For those who received the 22-month booster immunization, bloodwas sam-
pled just prior to booster immunization and at 7 and 21 days after immunization. The 7-day
bloodwas taken to look for evidence of early response suggestive of immunologicalmemory.
Finally those immunized with a two-dose schedule of the clade 2 vaccine as a primary course
had blood sampled prior to each immunization and 21 days after the second dose.
Booster vaccines. The vaccines were inactivated, split-virion preparations of vaccine
strains; clade 1: A/Vietnam/1194/2004/NIBRG-14 (H5N1) (7.5 μg HA without adjuvant) or
clade 2: A/Indonesia/5/05-RG2 (H5N1) (30 μg with Al(OH)3), propagated in embryonated
eggs. The dose of Al(0H)3, used as the adjuvant, was 600 μg/dose (expressed as the content of
Al3+). Both formulations were presented in ready-to-usemulti-dose vials from which 0.5 ml
were withdrawn and injected intramuscularly into the deltoid muscle using a standard syringe
and 25 G, 25 mm needle.
Safety and Reactogenicity Analysis
After each immunization participants were monitored for 30 minutes for immediate reactions.
Participants kept diaries in which they recorded any solicited (prelisted) local or systemic reac-
tions that occurredup to 7 days after immunization. Specifically participants were asked to
record injection site induration, injection site ecchymosis, temperature, malaise and shivering
for 3 days after vaccination. Participants were also asked to record any other adverse event that
occurredup to 21 days after immunization. Serious adverse events were collected throughout
the study. Participants were followed up between 7 and 28 months (12 months for the group
receiving the clade 1 A(H5N1)/Vietnam booster; 22 months for participants who took part in
the primary phase of the study only; 28 months for participants who received the clade 2 A/
Indonesia booster at 22 months and 7 months for 50 additional participants primed with the
clade 2 A(H5N1N)/Indonesia.
Antibody Response
Serum samples were used for antibody titration against one of the vaccine strains (clade 1 or
clade 2) using haemagglutination inhibition (HI) and seroneutralization (SN) assays.
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The HI assay reflects the ability of the specific anti-influenza virus antibodies to inhibit hae-
magglutination of erythrocytesby influenza virus as previously described [8]. Briefly, the HI
assays were performed on serial twofold dilutions of all available samples using horse erythro-
cytes (lower detection limit 1:8; seroresponse threshold of 1:32).
The SN assay is based on the ability of antibodies to inhibit the infection of Madin-Darby
canine kidney (MDCK) cell culture, as previously described [8]. Briefly, inactivated human
serumwas incubated with virus then added to the MDCK cell culture. After an overnight incu-
bation, enzyme-linked immunosorbent assay was used to measure the degree of infection of
the MDCK. The lower level of detection of this assay was 1:20.
In all assays samples were tested in duplicate and the titer analyzed was the geometricmean
of the duplicates, expressed as the reciprocal of dilution. Samples without detectable antibody
activity were assigned the titer of half the assay detection limit. These analyses were performed
under blinded conditions at the Public Health England laboratories (Colindale, London, UK).
Statistical Analysis
Sample size for the additional participants receiving a primary vaccination series of the clade 2
vaccine A(H5N1)/Indonesia, was arbitrarily set at 50 subjects. The sample size required to
determine the booster response to clade 2 A(H5N1)/Indonesia was deemed to be lower than
the initial cohort size, as only half the original study population were eligible to continue in the
study, i.e. those who received the higher dose vaccine during the primary phase. Accordingly,
participants at centre 4 were not invited to take part in the booster phase of the study. The min-
imal data sets underlying the findings are available to interested researchers who in the first
instance may request access to anonymized patient-level data and clinical study documents at
www.clinicalstudydatarequest.com. If further assistance is required then the corresponding
author is to be contacted.
The study was descriptive and no formal statistical comparisons between groups have been
made. The results are presented with 95% confidence intervals of point estimates calculated
using normal approximation for quantitative data and exact binomial distribution (Clopper-
Pearson method) for proportions. The population analyzed for all the timepoints presented here
are the full analysis set. A per-protocol analysis was pre-designated for the A(H5N1) vaccine
naïve group receiving the primary course with clade 2 vaccine, however there were no protocol
deviations in this group therefore the per protocol and full analysis set were equivalent. For the
groups that received either booster vaccination the full analysis set is defined as all those who
received the booster immunization. The analysis included all data available at each timepoint.
HI data are expressed as GMT’s in accordance with criteria based on those defined for the HI
method by the committee for Medicinal Products for Human Use (CHMP) for seasonal influenza
vaccines which are applied to pandemic vaccines in absence of specific alternative criteria. These
criteria are: a seroprotection rate (% withHI titers 40 dil-1) of over 70%; a rate of seroconversion
or significant titer increase (pre-vaccination titer of< 8 and post-vaccination titer 32,
or 4-fold titer increase betweenpre and post titers) of over 40% and an increase in geometric
mean titer ratio (GMTR) betweenpost and pre vaccination titer by over 2.5. In adults over the age
of 60 these criteria are modified to a seroprotection rate of over 60%, seroconversion rate or signifi-
cant increase in titer of over 30% and a GMTR of over 2 [9]. It is recommended that antibody per-
sistence is also evaluated to help guide re-immunization practices, however there are no formal
immunogenicity criteria provided. Only data relating to HI antibodies are presented here.
Analyses were performed by the Sanofi Pasteur Biostatistics Department,Marcy I’Etoile,
France, using SAS software version 8.2 (SAS Institute, CaryNC, USA)) and were independently
validated by the Oxford Vaccine Group, University of Oxford, using SAS version 9.3 (M.V.).
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Results
At 6-months after the start of the primary phase of the study 587 out of the original 600 partici-
pants remained eligible to continue in the study (Fig 1). For the 6-month, 7.5 μg booster arm,
155 participants completed the study at this point. For the 22-month, clade 2, 30 μg alum-adju-
vanted booster arm 118 participants completed the study at this point. Antibody persistence
after primary vaccination was evaluated at 6, 15 and 22 months in 587, 409 and 192 partici-
pants, respectively. Additional information on the procedures performed at each study visit
can be found in S1 Fig (trial flow charts) that compliments the Fig 1.
Safety and Reactogenicity
In total 33 serious adverse events (SAEs) have been reported in this phase of the study, that is
up to 42 days after the start of the study. SAEs that occurred in the primary phase are reported
in the primary phase publication [8]. There were no SAE in the 21 days following receipt of
either strength of booster or primary clade 2 vaccination. None of the SAEs were considered by
the investigators to be related to vaccination.
Up to 21 days after the booster dose of the 7.5 μg clade 1 A(H5N1)/Vietnam vaccine the per-
centage of adults aged between 18 and 60 years reporting at least one solicited reaction was
50% in those primed with the high dose adjuvanted vaccine and 35.9% in those primed with
the low dose non-adjuvanted vaccine. In adults aged over 60 years at least one solicited event
was reported by 19.5% and 27.8% in the high dose and low dose priming groups respectively.
Up to 21 days after booster immunization with the high-dose alum-adjuvanted clade 2 A/
Indonesia vaccine 74.6% of adults aged between 18 and 60 reported at least one solicited injec-
tion site reaction and 42.4% at least one solicited systemic reaction whilst 36.8% and 33.3% of
those aged over 60 reported at least one solicited injection site and systemic reaction,
respectively.
Most common reactions in both groups were pain at the injection site, headache and mal-
aise which started within 3 days of vaccination. Unsolicited reactions that started after 21 days
were considered not related to the vaccine. A break down of the type of reactions in the first 7
days after immunization is given in Table 1.
In the naïve group (18–60 years old) who received a primary course of the clade 2 A
(H5N1)/Indonesia vaccine no SAEs were reported. Overall 72% of participants experienced a
solicited reaction within 21 days of immunization. Injection site pain and headache were the
most commonly reported reactions in the first 7 days after immunization (Table 1).
Immunogenicity
Antibody persistence. At 6 months after primary immunization with the 7.5 μg clade 1 A
(H5N1)/Vietnam vaccine the percentage of individuals who had antibody levels above the
threshold for seroprotection (defined as HI antibody titer32) was 6.2% in the 18 to 60 years
group and 14.4% in the over 60 years group (Table 2).
In the group who had received the 30 μg adjuvanted clade 1 A(H5N1)/Vietnam vaccine,
6.2% of participants aged 18 to 60 and 18.9% of participants aged over 60 had HI titres> 32.
Again these levels decreasedwith time (Table 2).
Booster and primary responses. Booster response to 7.5 μg clade 1 A/Vietnam vaccine at
6 months (Table 3).
The response to this booster vaccine at 6 months after the primary immunisation as mea-
sured by HI antibody did not meet any of the CHMP criteria in either of the two age groups.
Booster response to 30μg with adjuvant clade 2 A/Indonesia vaccine at 22 months (Table 4).
Avian Influenza Vaccination in Adults
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The booster response was tested against both clade 1 and 2 viruses. At 7 days after the
booster immunization the GMTR was above the threshold required by the CHMP (fulfilling 1
out 3 requirements) in the 18 to 60 year group against both clade 1 and clade 2 strains but not
in the over 60 age group.
By 21 days after immunization in the 18 to 60 year age group 2 out of 3 CHMP criteria
(seroconversion rate and GMTR) were fulfilledwhen tested against the clade 2 virus and a sin-
gle criterion (GMTR) was met when tested against the clade 1 virus. In the over 60 year group
the only CHMP criterionmet was the GMTR for both of the viral strains tested.
Primary Response to clade 2 vaccine (Table 5).
In the naïve group who received the clade 2 vaccine only, prior to immunization there was
no evidence of prior immunity to the clade 2 A/Indonesia virus. Twenty-one days after a single
dose of vaccine one CHMP criterion (GMTR over 2.5) was met. This did not change 21 days
after the second immunization. The demographics of the booster and naïve group are given in
the supplementary material.
Discussion
This study investigated the potential usefulness of a prime-boost vaccination strategy using
two different influenza A(H5N1) strains to induce cross clade protection. The data show that a
Table 2. Antibody persistence as defined by HI antibody titer at 6/15/22-months following the first vaccination with clade 1 A/Vietnam/1194/2004/
NIBERG-14.
Age Groups 160 years > 60 years
Primary vaccination 7.5 μg 30 μg + Adjuvant 7.5 μg 30 μg + Adjuvant
Time (months) since
vaccination
6 (n = 146) 6 (n = 146) 15 (n = 98) 22 (n = 95) 6 (n = 146) 6 (n = 148) 15 (n = 101) 22 (n = 94)
% subjects with GMT 32
(95% CI)
6.2 (2.9; 11.4) 6.2 (2.9; 11.4) 3.1 (0.6; 8.7) 1.1 (0.0; 5.7) 14.4 (9.1;
21.1)
18.9 (13.0;
26.2)
12.9 (7.0;
21)
11.7 (6.0; 20)
GMT (95% CI) 5.43 (4.85;
6.08)
5.99 (5.33;
6.73)
4.6 (4.20;
5.06)
4.33 (4.03;
4.66)
7.63 (6.41;
9.08)
9.42 (7.78;
11.42)
6.8 (5.55;
8.30)
6.37 (5.22;
7.76)
GMT: Geometric mean titer n = number of participants
doi:10.1371/journal.pone.0165384.t002
Table 3. 21 Day Booster response to 7.5 μg clade 1 A/Vietnam/1194/2004/NIBERG-14 6-months after the first vaccination.
Age group 18 to 60 years > 60 years
Primary vaccine dose 7.5 μg (N = 39) 30 μg + Adjuvant (N = 38) 7.5 μg (N = 36) 30 μg + Adjuvant(N = 41)
EMA threshold
GMT (95% CI) None 8.67 (6.32; 11.89) 9.96 (7.17; 13.82) 11.53 (7.56; 17.59) 18.8 (12.5; 28.3)
GMTR (95% CI) >2.5 1.59 (1.22; 2.06) 1.45 (1.21; 1.75)
GMTR (95% CI) > 2# 1.31 (1.06; 1.62) 1.34 (1.09; 1.67)
Seroconversion* % (95% CI) > 40% 10.3 (2.9; 24.2) 2.6 (0.1; 13.8)
Seroconversion* % (95% CI) > 30%# 2.8 (0.1; 14.5) 9.8 (2.7; 23.1)
Seroprotection (titre 40) % (95% CI) > 70% 12.8 (4.31; 27.4) 13.2 (4.4; 28.1)
Seroprotection (titre 40) % (95% CI) > 60%# 19.4 (8.2; 36.0) 29.3 (16.1; 45.5)
n = number of participants
EMA: European Medicines Authority
GMT: Geometric mean titer
GMTR: Geometric mean titer ratio (post-vaccination titer/pre-vaccination titer)
*Seroconversion: subjects with pre-vaccination titers < 8 and post-vaccination titres > 32 or significant increase in titres defined as pre-vaccination titre < 8
with at least a 4-fold increase in post-vaccination titers
# Modified EMA criteria for adults aged over 60 years of age
doi:10.1371/journal.pone.0165384.t003
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heterologous booster vaccine strain can induce cross-clade reactivity. Despite the fact that the
primary vaccination schedule had induced antibody responses that met CHMP criteria in
some groups, 6 months after the booster dose antibody levels had waned below the CHMP
thresholds established for primary vaccination. It is important to stress here that no CHMP cri-
teria exist for the duration of antibody persistence and the extent of cross-clade reactivity of
influenza vaccines. It may not be indicated to appreciate the value of this prime-boost strategy
using a possibly non-appropriate scoring system [9].
Table 4. Booster response to 30 μg adjuvanted clade 2/ Indonesia/5/05-RG2 vaccine at 22 months following the first vaccination.
18 to 60 years > 60 years
Strain used to test
response
Clade 1
(Vietnam)
Clade 2
(Indonesian)
Clade 1
(Vietnam)
Clade 2
(Indonesian)
EMA
threshold
Time after vaccination
(days)
N = 59 N = 59 N = 57 N = 57
GMT (95% CI) None 7 12.1 (9.35; 15.8) 12.6 (9.56; 16.5) 8.25 (6.25; 10.9) 6.16 (5.02; 7.56)
21 14.4 (10.8; 19.2) 15.2 (11.3; 20.3) 10.7 (7.71; 14.9) 9.84 (7.06; 13.7)
GMTR (95% CI) >2.5 or > 2# 7 2.93 (2.28; 3.77) 3.07 (2.34; 4.03) 1.54 (1.25; 1.90) 1.49 (1.21; 1.82)
21 3.47 (2.63; 4.59) 3.71 (2.78; 4.94) 2.01 (1.50; 2.71) 2.39 (1.72; 3.33)
Seroconversion* % (95%
CI)
> 40% or 30%# 7 27.1 (16.4; 40.3) 28.8 (17.8; 42.1) 12.5 (5.2; 24.1) 8.9 (3.0; 19.6)
21 39 (26.5; 52.6) 42.4 (29.6; 55.9) 17.9 (8.9; 30.4) 21.4 (11.6; 34.4)
GMTtitre 32% (95% CI) > 70%
or > 60%#
7 27.1 (16.4; 40.3) 28.8 (17.8; 42.1) 22.8 (12.7; 35.8) 10.5 (4.0; 21.5)
21 39 (26.5; 52.6) 42.2 (29.6; 55.9) 26.3 (15.5; 39.7) 22.8 (12.7; 35.8)
EMA: European Medicines Authority
GMT: Geometric mean titer
GMTR: Geometric mean titer ratio (post-vaccination titer/pre-vaccination titer)
*Seroconversion: subjects with pre-vaccination titers < 8 and post-vaccination titres > 32 or significant increase in titres defined as pre-vaccination titre < 8
with at least a 4-fold increase in post-vaccination titers about 3 weeks after vaccination
# Modified EMA criteria for adults aged over 60 years of age
Numbers shown in bold are those which meet the specified EMA criterion
doi:10.1371/journal.pone.0165384.t004
Table 5. Primary response following clade 2 A/Indonesia /5/05-RG2 as determined by HIH method.
EMA threshold Time after vaccination (days) Primary vaccination 30 μg + adjuvant (n = 50)
GMT (95% CI) None 0 4.0 (4.0; 4.0)
21 4.4 (4.08; 4.760
42 12.8 (8.84; 18.6)
GMTR % (95% CI) > 2.5 21 2.9 (2.08; 4.06)
42 3.20 (2.21; 4.64)
Seroconversion% (95% CI) > 40% 21 0.0 (0.0; 7.1)
42 26.0 (14.6; 40.3)
Seroprotection % (titre 32) > 70% 0 0.0 (0.0;7.1)
21 0.0 (0.0; 7.1)
42 26 (14.6; 40.3)
n = number of participants
EMA: European Medicines Authority
GMT: Geometric mean titer
GMTR: Geometric mean titer ratio (post-vaccination titer/pre-vaccination titer)
*Seroconversion: subjects with pre-vaccination titers < 8 and post-vaccination titres > 32 or significant increase in titres defined as pre-vaccination titre < 8
with at least a 4-fold increase in post-vaccination titers
doi:10.1371/journal.pone.0165384.t005
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Antibody Persistence
Few reports are available on antibody persistence with influenza A(H5N1) vaccines exceding a
6 month periodwhereas a pandemic threat can persist for several years. Lin et al., (2009)
reported that 6-months after immunization with low dose, alum-adjuvanted, whole virion A
(H5N1) vaccine antibodies were only present in 4.8% to 20.8% of adults aged under 60 years
and thus failed to meet any CHMP at this time point [10]. In contrast, it has been demon-
strated that antibodies induced by a low dose influenza A(H5N1) vaccine formulated with an
oil-in-water adjuvant persist at levels that meet all 3 CHMP criteria 6-months after immuniza-
tion [11]. In head-to-head comparisons of low-dose, unadjuvanted vaccines and oil-in-water
emulsion-adjuvanted vaccines, the latter were shown to elicit higher antibody titres that per-
sisted much longer in both young and old adults [12, 13].
In the present study participants were followed for 22 months following the first immuniza-
tion, which is the longest follow-up period reported. Six months after primary vaccination the
magnitude of HI titres differedmore by age group than by primary vaccination group (low-
dose, unadjuvanted vs. high-dose, alum-adjuvanted). In the younger age group 6% of partici-
pants had HI titres detected at 6 months, irrespective of the type of vaccine administered. In
the older age group 14.4% and 18.9% had detectableHI titres with the low- and high-dose vac-
cine, respectively. This trend continued for 22 months after immunization and may reflect the
effect of prior priming via natural exposure or seasonal influenza vaccine in the older group. In
fact even at baseline, prior to A(H5N1) immunization, 16% of the older age group had elevated
HI titres; similar results have been found by other investigators [14,15].
Cross-Clade Immunity
Vaccine-induced cross-clade immune response is defined as the ability to induce immune
responses against pathogen strains that are genetically distinct from the strain(s) used to pro-
duce the vaccine [16]. Practically this infers that immunization with a vaccine containing anti-
gen(s) from one clade of pandemic virus may elicit some degree of protection against a
genetically distinct virus strain. A cross-reactive immune response betweenH5N1 vaccines
would potentially allow dose-sparing during subsequent waves of the pandemic. Cross-reactiv-
ity between avian influenza viral clades has previously been demonstrated using vaccines con-
taining oil-in-water emulsions as adjuvants, such as MF59 and AS03 and whole-virion
vaccines [17–22]. A primary course of a low-dose clade 1 vaccine containing an oil-in-water
adjuvant induced antibodies against a clade 2 virus in 77% of study participants [21]. When
the same antigen was administered without any adjuvant no cross-reactive response was
observed, demonstrating the importance of the adjuvant for the induction of cross-reactivity
[22]. Wu et al., (2009) used a two-dose schedule of whole-virion vaccine containing an alum-
adjuvant. Twenty-eight days after the second vaccine dose seroconversion was induced against
two heterologous clade 2 strains tested in more than 40% of the participants 28 days, thus
meeting 1 out of 3 CHMP criteria [23]. To our knowledge no direct comparisons of cross-reac-
tivity between vaccines containing oil-in-water-based adjuvants and alum-adjuvanted vaccines
or alum-adjuvanted vaccines and non-adjuvanted vaccines have been performed. Studies that
have compared immunogenicity of alum-adjuvanted vaccines with that of non-adjuvanted vac-
cines suggest that aluminium does not improve the immunogenicity of the vaccines, in particu-
lar when low antigen doses are used [24, 25]. Whether the presence of alum contributes to
cross-reactivity remains unanswered.
The main study limitation stemmed from the lower than expected antibody responses to the
low dose vaccine described in the primary phase of the study [8] this meant that that only
those who received the high dose vaccine with adjuvant were invited to have the Clade 2
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booster vaccine. The loss of half of all study participants by the amendment to study design
meant that there was inadequate power for a formal statistical analysis for the booster phase of
the study therefore centre 4 was not included on grounds of commercial feasibility to allow the
remainder of the study to go one. The amended study design also accounts for the arbitrary
sample size of the group who received primary vaccination with the clade 2 vaccine.
In conclusion antibody cross-reactivity betweenA(H5N1) clades suggests that in principle a
prime-boost vaccination strategymay provide both early protection at the start of a pandemic
and improved antibody responses to specific vaccination once available. Further criteria to
assess this strategy are needed.
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